# Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease

> **NCT03195231** · PHASE4 · UNKNOWN · sponsor: **Beijing Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Antidepressive Agents

## Interventions

- **DRUG:** Wuling Powder
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03195231
- **Lead sponsor:** Beijing Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-06-25
- **Primary completion:** 2019-12-15
- **Final completion:** 2020-01-15
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2017-06-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03195231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03195231, "Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03195231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*